New findings help explain how COVID-19 overpowers the immune system

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondria are one of the first lines of defense against COVID-19 and identifies key differences in how SARS-CoV-2, the virus that causes COVID-19, interacts with mitochondrial genes when compared to other viruses.

These differences offer possible explanations as to why older adults and people with metabolic dysfunction have more severe responses to COVID-19 than other individuals, and they also provide a starting point for more targeted experiments that may help identify therapeutics, said senior author Pinchas Cohen, professor of gerontology, medicine and biological sciences and dean of the USC Leonard Davis School.

"If you already have mitochondrial and metabolic dysfunction, then you may, as a result, have a poor first line of defense against COVID-19. Future work should consider mitochondrial biology as a primary target for SARS-CoV-2 and other coronaviruses," he said.

The study, published January 8 in the Nature journal Scientific Reports, expands on recent findings that COVID-19 mutes the body's innate inflammatory response and reports that it seems to be doing so by telling mitochondrial genes what to do.

"We already knew that our immune response was not mounting a successful defense to COVID-19, but we didn't know why," said lead author Brendan Miller, a senior doctoral student in the Cohen Lab at the USC Leonard Davis School. "What we did differently was look at how the virus specifically targets mitochondria, a cellular organelle that is a crucial part of the body's innate immune system and energy production."

Making use of the vast amounts of public data being uploaded in the early days of the virus outbreak, the research team performed RNA sequencing analyses that compared mitochondrial-COVID interactions to those of other viruses: respiratory syncytial virus, seasonal influenza A virus, and human parainfluenza virus 3. These reanalyses identified three ways in which COVID-19, but not the other viruses, mutes the body's cellular protective response.

Chief among their findings is that SARS-CoV-2 uniquely reduces the levels of a group of mitochondrial proteins, known as Complex One, that are encoded by nuclear DNA. It is possible that this effect "quiets" the cell's metabolic output and reactive oxygen species generation, that when functioning correctly, produces an inflammatory response that can kill a virus, they say.

"COVID-19 is telling the cell not to make these Complex One-related proteins. That could be one way the virus continues to propagate," said Miller, who notes that this, along with the study's other observations, still needs to be validated in a targeted experiment.

The study also revealed that SARS-CoV-2 does not change the levels of the messenger protein, MAVS mRNA, that usually tells the cell an attack has happened. Normally, when this protein gets activated, it functions as an alarm system, warning the cell to self-destruct so that the virus cannot replicate, Miller said.

In addition, the researchers found that genes encoded by the mitochondria were not being turned on or off by SARS-CoV-2 - a process that is believed to produce energy that can help the cell evade a virus - at rates to be expected when confronted with a virus.

"This study adds to a growing body of research on mitochondrial-COVID interactions and presents tissue- and cell-specific effects that should be carefully considered in future experiments," said Cohen.

Brendan Miller, Ana Silverstein, Melanie Flores, Kevin Cao, Hiroshi Kumagai, Hemal H. Mehta, Kelvin Yen, Su- Jeong Kim, Pinchas Cohen.
Host mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples.
Scientific Reports volume 11, 2021. doi: 10.1038/s41598-020-79552-z

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...